Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | FCER2 | P06734 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682047 | 0.88 | HPGDS (0.53) | HPGDSFCER2MME | |
| SCHEMBL4677881 | 0.87 | FCER2 (0.52) | FCER2MMP3MMP9MME | |
| SCHEMBL4677385 | 0.84 | FCER2 (0.45) | HPGDSFCER2MMP3MMP9SLC1A1 | |
| SCHEMBL4681415 | 0.84 | HPGDS (0.46) | HPGDSMME | |
| SCHEMBL4681161 | 0.82 | HPGDS (0.53) | HPGDSFCER2MME | |
| SCHEMBL23356941 | 0.79 | SLC1A1 (0.54) | HPGDSFCER2MMP3MMP9ROCK1 | |
| SCHEMBL23356943 | 0.79 | SLC1A1 (0.54) | HPGDSFCER2MMP3MMP9ROCK1 | |
| SCHEMBL4681467 | 0.79 | MC5R (0.51) | HPGDS | |
| SCHEMBL4680585 | 0.78 | CTSS (0.45) | HPGDSFCER2MMP3MMP9ROCK1 | |
| SCHEMBL4683513 | 0.76 | SLC1A1 (0.41) | FCER2MMP3MMP9SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | claimed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | claimed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | HPGDS 1032/4885SRC 1206/4885FCER2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.